We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Y402H Comlement Factor H Polymorphism and Age-Related Macular Degeneration in the Austrian Population

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2007 by Rudolf Foundation Clinic.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00533754
First Posted: September 21, 2007
Last Update Posted: September 21, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Rudolf Foundation Clinic
  Purpose

The aim of the study is to show a higher expression of the Y402H polymorphism in the complement factor H in patients with AMD compared to healthy individuals.

Additionaly a correlation between a subsided infection with chlamydia and patients with AMD and a factor H polymorphism will be investigated. An interrelationship with the VEGF-plasma level shall give more hints into the pathomechanism of AMD.


Condition Intervention
Age-Related Macular Degeneration Procedure: drawing blood

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Y402H Comlement Factor H Polymorphism and Age-Related Macular Degeneration in the Austrian Population

Resource links provided by NLM:


Further study details as provided by Rudolf Foundation Clinic:

Primary Outcome Measures:
  • higher expression of the Y402H polymorphism in the complement factor H in patients with AMD compared to healthy individuals

Secondary Outcome Measures:
  • a correlation between a subsided infection with chlamydia and patients with AMD and a factor H polymorphism will be investigated. An interrelationship with the VEGF-plasma level shall give more hints into the pathomechanism of AMD

Study Start Date: July 2006
Estimated Study Completion Date: November 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • man and women over 18 years old
  • Filled out informed consentBereitschaft zur Teilnahme
  • Diagnosis of non-exudative/ exudative age related macular dgeneneration

Exclusion Criteria:

  • inherited retinal diseases
  • other aquired retinal/ macular
  • missing informed consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00533754


Locations
Austria
Rudoulf foundation Clinic
Vienna, Austria, 1030
Sponsors and Collaborators
Rudolf Foundation Clinic
Investigators
Study Chair: Susanne Binder, M.D. Rudoulf Foundation Clinic
  More Information

ClinicalTrials.gov Identifier: NCT00533754     History of Changes
Other Study ID Numbers: EK 06-076-VK
First Submitted: September 20, 2007
First Posted: September 21, 2007
Last Update Posted: September 21, 2007
Last Verified: September 2007

Keywords provided by Rudolf Foundation Clinic:
age-related macular degeneration, genetics

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Complement Factor H
Complement Inactivating Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs